Ed Hurwitz is listed as an executive officer and director on 11 SEC Form D filings by 6 issuers between Mar 2009 and Jul 2025. Largest by amount reported sold: SUNESIS PHARMACEUTICALS INC (South San Francisco, CA — pharmaceuticals — 2009–2010; $28.5M reported sold to 18 investors), CALISTOGA PHARMACEUTICALS INC (Seattle, WA — pharmaceuticals — 2009; $25M reported sold to 17 investors), ViewPoint Therapeutics, Inc. (San Francisco, CA — biotechnology — 2016–2018; $20.9M reported sold to 17 investors), Arialys Therapeutics, Inc. (La Jolla, CA — biotechnology — 2022–2025; $14.8M reported sold to 7 investors), BioIntervene, Inc. (Brisbane, CA — pharmaceuticals — 2019–2021; $5.64M reported sold to 5 investors) and 1 more (all listed below).
What this means A repeat sponsor — 6 separate companies raised money with this person listed as executive officer and director, over about 16 years. Across those companies the filings report $99.7M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 11 public filings for Ed Hurwitz and found 13 differences: Bankruptcy case: Misfeldt v. JPMorgan Chase Bank, N.A; Bankruptcy case: Moldt v. US Bank NA; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.